Dark

Check out our Dark Pool Levels

DFFN
DIFFUSION PHARMACEUTICALS INC
stock NASDAQ

Inactive

Aug 16, 2023

6.60USD+11.675%(+0.69)234,038

Pre-market

0.00USD-100.000%(-5.91)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 20, 2021

07:02AM EST Diffusion Pharmaceuticals to Present at H.C. Wainwright GlobeNewswire Inc

Dec 16, 2021

09:04AM EST Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO Trial Benzinga

Dec 1, 2021

07:07AM EST Diffusion Pharmaceuticals Announced Issuance of U.S. Patent 11,185,523 'Use of Bipolar Trans Carotenoids With Chemotherapy and Radiotherapy for Treatment of Cancer' Benzinga

07:02AM EST Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523 GlobeNewswire Inc

Nov 22, 2021

07:05AM EST Diffusion Pharmaceuticals Doses First Participants In Altitude Trial Benzinga

Nov 10, 2021

07:25AM EST Diffusion Pharma Q3 Loss Per Share $0.12 Vs Loss $0.07 Last Year RTTNews

07:12AM EST Diffusion Pharmaceuticals Q3 EPS $(0.12) Down From $(0.07) YoY Benzinga

07:02AM EST -- Announces Intent to Develop TSC to Treat Hypoxic Tumors -- Altitude Trial Expected to Commence in November 2021 -- ILD-DLCO Trial Expected to Commence in Late December 2021 GlobeNewswire Inc

Oct 28, 2021

07:30AM EDT Diffusion Pharmaceuticals to Participate in the Alliance Global GlobeNewswire Inc

Oct 19, 2021

10:06AM EDT Diffusion Pharmaceuticals Granted U.S. Patent Titled 'Diffusion enhancing compounds and their use alone or with thrombolytics' Benzinga

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Sep 9, 2021

07:33AM EDT Diffusion Pharmaceuticals Issues Letter To Shareholders Benzinga

Sep 8, 2021

09:32AM EDT Diffusion Pharmaceuticals Sponsored Study Titled 'Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude' Posted To ClinicalTrials.Gov; Study Not Yet Recruiting Benzinga

07:32AM EDT Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. GlobeNewswire Inc

Aug 30, 2021

07:35AM EDT Diffusion Pharma Obtains FDA Clearance for its Investigational New Drug Application Benzinga

07:32AM EDT Phase 2 DLCOTrial inInterstitial Lung Disease Expectedto Begin in Q4Under New IND GlobeNewswire Inc

Aug 19, 2021

10:21AM EDT DFFN: Initial Indication for TSC to be Announced Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 11, 2021

07:44AM EDT Diffusion Pharmaceuticals Q2 End Cash, Cash Equivalents $43.3M Benzinga

07:41AM EDT Diffusion Pharmaceuticals Reports As Of June 30, 2021, Co. Had Cash And Cash Equivalents Of ~$43.3M Compared To $18.5M As Of December 31, 2020. Benzinga

07:32AM EDT -- Reports Improved Outcomes in Phase 1b COVID-19 Study and Positive Trendin Peripheral Oxygenation in Phase 1b TCOM Study -- Expects to Announce Initial Indication and Regulatory Pathway in Fourth Quarter of 2021 and Initiate Clinical Outcome Study in First Half of 2022 -- Anticipates Cash Runway through 2023, Including Completion of TSC Phase 2b Program GlobeNewswire Inc

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 11, 2021

07:01AM EDT DFFN: TSC Causes Dose Dependent Increase in Tissue Oxygenation in TCOM Trial Benzinga

Jun 30, 2021

11:14AM EDT Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation Benzinga

07:37AM EDT Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial Benzinga

07:35AM EDT Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)(Diffusion or the Company), an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, today announced topline results from the Companys Phase 1 trial of its lead product candidate, trans sodium crocetinate (TSC). GlobeNewswire Inc

Jun 28, 2021

08:35AM EDT Life Sciences Investor Forum today announced that the presentations from the June 24th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. GlobeNewswire Inc

Jun 21, 2021

08:35AM EDT Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry. GlobeNewswire Inc

07:35AM EDT Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)(Diffusion or the Company), an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, today announced that CEO Robert Cobuzzi, Jr., Ph.D., will present via webcast at the Life Sciences Investor Forum being held on June 24, 2021. GlobeNewswire Inc

Jun 18, 2021

07:42AM EDT Diffusion Reminds Stockholders To Vote On Proposals Listed In Proxy Statement RTTNews

07:35AM EDT Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)(Diffusion, we or the Company), an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, reminds stockholders to vote on the proposals listed in the Companys proxy statement in advance of its upcoming annual meeting. GlobeNewswire Inc

May 19, 2021

08:32AM EDT DFFN: Encouraging Data for TSC in COVID-19 Patients Benzinga

May 18, 2021

07:44AM EDT The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO Benzinga

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 10, 2021

10:24AM EDT Diffusion Pharma's Trans Sodium Crocetinate Associated With Improved Outcomes In COVID-19 Patients Benzinga

07:53AM EDT Diffusion Pharmaceuticals Reports Final Results From Phase 1b Study Of Trans Sodium Crocetinate In Hospitalized COVID-19 Patients Benzinga

07:50AM EDT Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b GlobeNewswire Inc

07:10AM EDT Diffusion Pharmaceuticals Q1 EPS $(0.06) Misses $(0.04) Estimate Benzinga

07:05AM EDT Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)(Diffusion or the Company), an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, today announced financial results for the first quarter of 2021 and provided a business update. GlobeNewswire Inc

May 7, 2021

04:11PM EDT Diffusion Pharmaceuticals Announced That On May 6 It Received Notice From Nasdaq Indicating That Company Was Not In Compliance With Nasdaq Listing Rule Benzinga

Mar 25, 2021

09:02AM EDT Diffusion Pharma Reports Completion Of Enrollment, Dosing In Transcutaneous Oxygen Monitoring Device Study Benzinga

09:01AM EDT Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM GlobeNewswire Inc

Mar 18, 2021

07:10AM EDT Diffusion Pharmaceuticals Doses First Participants In TCOM Study Benzinga

07:08AM EDT Diffusion Doses First Participants In TCOM Study RTTNews

07:05AM EDT Diffusion Pharmaceuticals Doses First Participants in TCOM Study GlobeNewswire Inc

Mar 17, 2021

07:05AM EDT Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)(Diffusion or the Company), an innovative biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, today announced financial results for 2020 and provided a business update. GlobeNewswire Inc

Mar 4, 2021

04:05PM EST Diffusion Pharmaceuticals, Inc. toPresent at the H.C. GlobeNewswire Inc

Feb 18, 2021

04:05PM EST Diffusion Pharmaceuticals Announces Full Exercise of GlobeNewswire Inc

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 17, 2021

04:13PM EST Diffusion Pharmaceuticals Announces Closing of $30 Million Bought GlobeNewswire Inc

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 16, 2021

09:18AM EST Diffusion Pharma Climbs After Completing Early-Stage TSC Study In COVID-19 Patients Benzinga

07:42AM EST Diffusion Pharmaceuticals Completes Phase 1b Study Of TSC In Hospitalized COVID-19 Patients Benzinga

07:35AM EST Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in GlobeNewswire Inc

Feb 12, 2021

06:03AM EST Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering to 29.26M Shares of Common Stock @$1.025/Share Benzinga

Feb 11, 2021

10:06PM EST Diffusion Pharma Increases Bought Deal Offering Of Common Stock To $30 Mln RTTNews

10:02PM EST Diffusion Pharmaceuticals Increases Previously Announced Bought GlobeNewswire Inc

05:56PM EST Diffusion Pharmaceuticals Announces $10M Bought Deal Offering Of 9.756M Shares Of Common Stock At $1.025/Share Benzinga

05:54PM EST Diffusion Pharmaceuticals Announces $10 Million Bought Deal GlobeNewswire Inc

Jan 26, 2021

04:55PM EST Diffusion Pharmaceuticals Received Written Notice From Nasdaq Confirming Co Has Regained Compliance Benzinga

Jan 11, 2021

07:30AM EST Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN)(Diffusion or the Company), today announced that the Company is participating in the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021. Conference specifics are as follows: GlobeNewswire Inc

Nov 19, 2020

05:20AM EST Diffusion Pharmaceuticals CEO Robert Cobuzzi Reported Purchase Wednesday of 14,000 Shares @ Avg Price of $0.66/Share in Form 4 Filing Benzinga

Nov 18, 2020

11:55AM EST Insider Buys Diffusion Pharmaceuticals Shares Benzinga

08:38AM EST Diffusion Pharmaceuticals Secretary Robert William Elder Buys 15,000 Shares @ Avg Price: $0.66 Benzinga

Nov 17, 2020

10:28AM EST HC Wainwright & Co. Downgrades Diffusion Pharmaceuticals to Neutral Benzinga

08:32AM EST H.C. Wainwright Downgrades Diffusion Pharmaceuticals to Neutral Benzinga

Nov 12, 2020

04:04PM EST Diffusion Pharmaceuticals Q3 EPS $(0.07) Up From $(0.60) YoY Benzinga

04:02PM EST Initiated and AdvancedClinical Trial Evaluating Lead Product Candidate in COVID-19 Patients GlobeNewswire Inc

Oct 19, 2020

08:11AM EDT Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer Benzinga

08:09AM EDT Diffusion Pharma Appoints Chris Galloway As Chief Medical Officer RTTNews

08:00AM EDT Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (Diffusion or the Company), today announced the appointment of Christopher D. Galloway, M.D. to Chief Medical Officer, effective immediately. Dr. Galloway will report to Robert Cobuzzi, Ph.D., Diffusions Chief Executive Officer. GlobeNewswire Inc

Sep 24, 2020

06:18PM EDT DFFN: First Patients Dosed in COVID-19 Trial Benzinga

08:00AM EDT Diffusion Pharmaceuticals Strengthens Management Team with GlobeNewswire Inc

Sep 11, 2020

08:30AM EDT Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (Diffusion or the Company), today announced its management will present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on September 14-16, 2020. Robert Cobuzzi, Ph.D., chief executive officer, will present a corporate overview of the Company on Tuesday, September 15th, at 3:00 p.m. Eastern time. GlobeNewswire Inc

Sep 10, 2020

09:37AM EDT Diffusion Doses First Two Patients With TSC In COVID-19 Clinical Trial RTTNews

08:01AM EDT Diffusion Pharmaceuticals Doses First Two Patients with TSC in GlobeNewswire Inc

08:00AM EDT Diffusion Pharmaceuticals Doses First Two Patients With TSC In COVID-19 Clinical Trial Benzinga

Sep 8, 2020

04:03PM EDT Diffusion Pharma Names Robert Cobuzzi Pres, CEO Benzinga

04:02PM EDT Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as GlobeNewswire Inc

Sep 1, 2020

04:05PM EDT Diffusion Pharmaceuticals Says Received Romanian Regulatory Approval To Begin Phase 1b COVID-19 Clinical Trial Benzinga

04:02PM EDT Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its GlobeNewswire Inc

Aug 24, 2020

08:32AM EDT From Benzinga's PreMarket Prep: Co-Host Dennis Dick Says If He Was In Plasma Stocks Right Now He Would Sell Them; Notes 'This Is A Gift I Would Ring The Register Right Now' Benzinga

Aug 10, 2020

08:30AM EDT Diffusion Pharmaceuticals Q2 EPS $(0.10) Misses $(0.06) Estimate Benzinga

08:00AM EDT Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (Diffusion or the Company), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the bodys ability to deliver oxygen to the areas where it is needed most, today reported financial results for the three and six months ended June 30, 2020 and provided a business update. GlobeNewswire Inc

Jul 27, 2020

04:03PM EDT Why Diffusion Pharmaceuticals Is Trading Lower Today Benzinga

02:54PM EDT Mid-Afternoon Market Update: Nasdaq Surges 140 Points; MediciNova Shares Spike Higher Benzinga

12:07PM EDT Mid-Day Market Update: Gold Jumps 2%; WiMi Hologram Cloud Shares Plummet Benzinga

08:22AM EDT Diffusion Gets FDA Guidance For International Phase 1b/2b COVID-19 Clinical Program With TSC RTTNews

08:04AM EDT Diffusion Pharmaceuticals Receives FDA Guidance For International Phase 1b/2b COVID-19 Clinical Program With TSC; Says Guidance Being Incorporated Into Global Study Protocol, Enrollment Of First Patient Now Expected In August Benzinga

08:00AM EDT Guidance being incorporated into global study protocolEnrollment of first patient now expected in August GlobeNewswire Inc

Share